Sarepta Therapeutics: Recombinant DNA Molecule Patent-Eligibility Under 35 U.S.C. § 101 March 11, 2026 On February 20, 2026, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a decision ...
Sarepta Therapeutics: Recombinant DNA Molecule Patent-Eligibility Under 35 U.S.C. § 101 Author: David Inglefield March 11, 2026 On February 20, 2026, the U.S. Court of Appeals for the Federal Circuit ...
Supreme Court Denies Cert in PatentEligibility Cases and the Skinny Label Case May 15, 2023 Today the Supreme Court denied cert in GSK v. Teva in which the Solicitor General filed a brief in support ...
In PatentEligibility It's the Claim That Is the Name of the Game* December 18, 2023 Recently Judge Connolly, Chief Judge of the District Court of Delaware had an opportunity of deciding three motions ...
Solicitor General on PatentEligibility December 16, 2019 The Solicitor General (SG) was invited by the Supreme Court to provide comments on the certiorari petitions filed by Berkheimer and Hikma ...
A Method of Preparation" and PatentEligibility Under Section 101 March 30, 2020 Before LOURIE, MOORE, and REYNA, Circuit Judges. Illumina, Inc. and Sequenom, Inc. (“Illumina”) filed suit against ...
Ex Parte Jadran Bandic – PatentEligibility Analysis After Berkheimer June 4, 2018 In Ex Parte Bandic, the PTAB (“the Board”) has given an insight into how the Office intends to examine patent ...
Federal Circuit Rules in Favor of PatentEligibility April 16, 2018 On April 13 the Federal Circuit affirmed the lower court decision in Vanda Pharm. Inc. v. West-Ward Pharm. Int’l. Ltd., appeal ...
PatentEligibility Under 35 U.S.C. 101 of Articles of Manufacture November 6, 2019 FYF-JB, LLC sued Pet Factory, Inc. for infringing its U.S. Patent 9,681,643 (“the ‘643 patent”) covering a tug ...
The Trials and Tribulations of PatentEligibility of Natural Products at the PTAB March 8, 2018 As patent prosecution practitioners, we often look for direction from the judges at the PTAB, particularly ...